Advertisement

Clinical Reviews in Allergy & Immunology

, Volume 54, Issue 1, pp 131–146 | Cite as

Cutaneous Granulomatosis: a Comprehensive Review

  • Benedetta Terziroli Beretta-Piccoli
  • Carlo Mainetti
  • Marie-Astrid Peeters
  • Emmanuel Laffitte
Article

Abstract

Cutaneous granulomatosis is a heterogeneous group of diseases, characterized by a skin inflammatory reaction triggered by a wide variety of stimuli, including infections, foreign bodies, malignancy, metabolites, and chemicals. From a pathogenic point of view, they are divided into non-infectious and infectious granulomas. Pathophysiological mechanisms are still poorly understood. Non-infectious granulomatous skin diseases include granuloma annulare, necrobiosis lipoidica, rheumatic nodules, foreign body granulomas, cutaneous sarcoidosis, and interstitial granulomatous dermatitis. Necrobiosis lipoidica is more frequent in diabetic patients. Infectious granulomas of the skin are caused by mycobacteria, in particular Mycobacterium tuberculosis or atypical mycobacteria; parasites, such as Leishmania; or fungi. Pathogenic mechanisms of M. tuberculosis-related granuloma are discussed. From a clinical point of view, it is useful to divide cutaneous granulomatosis into localized and more disseminated forms, although this distinction can be sometimes artificial. Three types of localized granulomatous lesions can be distinguished: palisaded granulomas (granuloma annulare, necrobiosis lipoidica, and rheumatoid nodules), foreign body granulomas, and infectious granulomas, which are generally associated with localized infections. Disseminated cutaneous granulomas can be divided into infectious, in particular tuberculosis, and non-infectious forms, among which sarcoidosis and interstitial granulomatous dermatitis. From a histological point of view, the common denominator is the presence of a granulomatous inflammatory infiltrate in the dermis and/or hypodermis; this infiltrate is mainly composed of macrophages grouped into nodules having a nodular, palisaded or interstitial architecture. Finally, we propose which diagnostic procedure should be performed when facing a patient with a suspected cutaneous granulomatosis.

Keywords

Granulomatous disease Granuloma annulare Necrobiosis lipoidica Foreign body granulomas Infectious granulomas Sarcoidosis Interstitial granulomatous dermatitis 

Abbreviations

DCs

Dendritic cells

T cells

T lymphocytes

MΦs

Macrophages

TLR

Toll-like receptors

NOD

Nucleotid-binding oligomerization domain

DAMPs

Damage-associated molecular patterns

PAMPs

Pathogen-associated molecular pattern

IFN

Interferon

M1

Macrophages 1

M2

Macrophages 2

IL

Interleukin

APCs

Antigen presenting cells

Th

T helper cells

GA

Granuloma annulare

HLA

Human leukocyte antigen

TNF

Tumor necrosis factor

NL

Necrobiosis lipoidica

P.

Propionibacterium

IGD

Interstitial granulomatous dermatitis

PNGD

Palisaded neutrophilic and granulomatous dermatitis

RGD

Reactive granulomatous dermatitis

Mtb

Mycobacterium tuberculosis

DG-SIGN

DC-specific intercellular adhesion molecule-3-grabbing non-integrin

PDT

Photodynamic therapy

MAL-PDT

Methyl aminolevulinate-photodynamic therapy

PUVA

Psoralen and UVA

M.

Mycobacterium

PCR

Polymerase chain reaction

Notes

Acknowledgements

We kindly acknowledge the assistance of Professor Diego Vergani (MD, PhD) for his critical review of the pathogenesis section, and Professor Gürkan Kaya (MD) for providing the histological pictures.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Informed Consent

When necessary, informed consent has been collected from patients.

References

  1. 1.
    Lo Schiavo A, Ruocco E, Gambardella A, O’Leary RE, Gee S (2014) Granulomatous dysimmune reactions (sarcoidosis, granuloma annulare, and others) on differently injured skin areas. Clin Dermatol 32(5):646–653.  https://doi.org/10.1016/j.clindermatol.2014.04.012 PubMedCrossRefGoogle Scholar
  2. 2.
    Asai J (2017) What is new in the histogenesis of granulomatous skin diseases? J Dermatol 44(3):297–303.  https://doi.org/10.1111/1346-8138.13662 PubMedCrossRefGoogle Scholar
  3. 3.
    Lapointe A-K, Laffitte E (2009) Disseminated cutaneous granulomatosis. Rev Med Suisse 5(900):902–906Google Scholar
  4. 4.
    Masson E Granulomes cutanés non infectieux. In: EM-Consulte. http://www.em-consulte.com/article/195548/granulomes-cutanes-non-infectieux. Accessed 16 Nov 2017
  5. 5.
    Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17(1):1–14.  https://doi.org/10.1093/intimm/dxh186 PubMedCrossRefGoogle Scholar
  6. 6.
    Takeda K, Akira S (2015) Toll-like receptors. Curr Protoc Immunol 109:14.12.1–14.1210.  https://doi.org/10.1002/0471142735.im1412s109 CrossRefGoogle Scholar
  7. 7.
    Ito T, Connett JM, Kunkel SL, Matsukawa A (2013) The linkage of innate and adaptive immune response during granulomatous development. Front Immunol 4:10.  https://doi.org/10.3389/fimmu.2013.00010 PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 229(2):176–185.  https://doi.org/10.1002/path.4133 PubMedCrossRefGoogle Scholar
  9. 9.
    Boros DL (1978) Granulomatous inflammations. Prog Allergy 24:183–267PubMedGoogle Scholar
  10. 10.
    Boros DL (2013) New perspectives on ancient granulomas. Front Immunol 4:345.  https://doi.org/10.3389/fimmu.2013.00345 PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Pieters J (2008) Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 3(6):399–407.  https://doi.org/10.1016/j.chom.2008.05.006 PubMedCrossRefGoogle Scholar
  12. 12.
    Hessian PA, Highton J, Kean A, Sun CK, Chin M (2003) Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 48(2):334–338.  https://doi.org/10.1002/art.10776 PubMedCrossRefGoogle Scholar
  13. 13.
    Okamoto Yoshida Y, Umemura M, Yahagi A, O’Brien RL, Ikuta K, Kishihara K, Hara H, Nakae S, Iwakura Y, Matsuzaki G (2010) Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol Baltim Md 1950 184(8):4414–4422.  https://doi.org/10.4049/jimmunol.0903332 Google Scholar
  14. 14.
    Anthony RM, Rutitzky LI, Urban JF, Stadecker MJ, Gause WC (2007) Protective immune mechanisms in helminth infection. Nat Rev Immunol 7(12):975–987.  https://doi.org/10.1038/nri2199 PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Friedman SJ, Winkelmann RK (1987) Familial granuloma annulare. Report of two cases and review of the literature. J Am Acad Dermatol 16(3):600–605.  https://doi.org/10.1016/S0190-9622(87)70080-2 PubMedCrossRefGoogle Scholar
  16. 16.
    Knoell KA (2009) Efficacy of adalimumab in the treatment of generalized granuloma annulare in monozygotic twins carrying the 8.1 ancestral haplotype. Arch Dermatol 145(5):610–611.  https://doi.org/10.1001/archdermatol.2009.92 PubMedCrossRefGoogle Scholar
  17. 17.
    Piette EW, Rosenbach M (2016) Granuloma annulare: clinical and histologic variants, epidemiology, and genetics. J Am Acad Dermatol 75(3):457–465.  https://doi.org/10.1016/j.jaad.2015.03.054 PubMedCrossRefGoogle Scholar
  18. 18.
    Avitan-Hersh E, Sprecher H, Ramon M, Bergman R (2013) Does infection play a role in the pathogenesis of granuloma annulare? J Am Acad Dermatol 68(2):342–343.  https://doi.org/10.1016/j.jaad.2012.08.023 PubMedCrossRefGoogle Scholar
  19. 19.
    Piette EW, Rosenbach M (2016) Granuloma annulare: pathogenesis, disease associations and triggers, and therapeutic options. J Am Acad Dermatol 75(3):467–479.  https://doi.org/10.1016/j.jaad.2015.03.055 PubMedCrossRefGoogle Scholar
  20. 20.
    Kapoor R, Piris A, Saavedra AP, Duncan LM, Nazarian RM (2013) Wolf isotopic response manifesting as postherpetic granuloma annulare: a case series. Arch Pathol Lab Med 137(2):255–258.  https://doi.org/10.5858/arpa.2011-0643-OA PubMedCrossRefGoogle Scholar
  21. 21.
    Terziroli Beretta-Piccoli B, Guillod C, Marsteller I, Blum R, Mazzucchelli L, Mondino C, Invernizzi P, Gershwin ME, Mainetti C (2017) Primary biliary cholangitis associated with skin disorders: a case report and review of the literature. Arch Immunol Ther Exp 65(4):299–309.  https://doi.org/10.1007/s00005-016-0448-0 CrossRefGoogle Scholar
  22. 22.
    Terziroli Beretta-Piccoli B, Invernizzi P, Gershwin ME, Mainetti C (2017) Skin manifestations associated with autoimmune liver diseases: a systematic review. Clin Rev Allergy Immunol 53(3):394–412.  https://doi.org/10.1007/s12016-017-8649-9 PubMedCrossRefGoogle Scholar
  23. 23.
    Wu W, Robinson-Bostom L, Kokkotou E, Jung HY, Kroumpouzos G (2012) Dyslipidemia in granuloma annulare: a case-control study. Arch Dermatol 148(10):1131–1136.  https://doi.org/10.1001/archdermatol.2012.1381 PubMedCrossRefGoogle Scholar
  24. 24.
    Marcoval J, Gómez-Armayones S, Valentí-Medina F, Bonfill-Ortí M, Martínez-Molina L (2015) Necrobiosis lipoidica: a descriptive study of 35 cases. Actas Dermosifiliogr 106(5):402–407.  https://doi.org/10.1016/j.ad.2015.01.004 PubMedCrossRefGoogle Scholar
  25. 25.
    Muller SA, Winkelmann RK (1966) Necrobiosis lipoidica diabeticorum. A clinical and pathological investigation of 171 cases. Arch Dermatol 93(3):272–281.  https://doi.org/10.1001/archderm.1966.01600210008002 PubMedCrossRefGoogle Scholar
  26. 26.
    O’Toole EA, Kennedy U, Nolan JJ et al (1999) Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. Br J Dermatol 140(2):283–286.  https://doi.org/10.1046/j.1365-2133.1999.02663.x PubMedCrossRefGoogle Scholar
  27. 27.
    Kota SK, Jammula S, Kota SK et al (2012) Necrobiosis lipoidica diabeticorum: a case-based review of literature. Indian J Endocrinol Metab 16(4):614–620.  https://doi.org/10.4103/2230-8210.98023 PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A (2013) Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol 69(5):783–791.  https://doi.org/10.1016/j.jaad.2013.05.034 PubMedCrossRefGoogle Scholar
  29. 29.
    Boateng B, Hiller D, Albrecht HP, Hornstein OP (1993) Cutaneous microcirculation in pretibial necrobiosis lipoidica. Comparative laser Doppler flowmetry and oxygen partial pressure determinations in patients and healthy probands. Hautarzt Z Dermatol Venerol Verwandte Geb 44:581–586Google Scholar
  30. 30.
    Ngo B, Wigington G, Hayes K, Huerter C, Hillman B, Adler M, Rendell M (2008) Skin blood flow in necrobiosis lipoidica diabeticorum. Int J Dermatol 47(4):354–358.  https://doi.org/10.1111/j.1365-4632.2008.03549.x PubMedCrossRefGoogle Scholar
  31. 31.
    Holland C, Givens V, Smoller BR (2001) Expression of the human erythrocyte glucose transporter Glut-1 in areas of sclerotic collagen in necrobiosis lipoidica. J Cutan Pathol 28(6):287–290.  https://doi.org/10.1034/j.1600-0560.2001.028006287.x PubMedCrossRefGoogle Scholar
  32. 32.
    Wakusawa C, Fujimura T, Kambayashi Y, Furudate S, Hashimoto A, Aiba S (2013) Pigmented necrobiosis lipoidica accompanied by insulin-dependent diabetes mellitus induces CD163+ proinflammatory macrophages and interleukin-17-producing cells. Acta Derm Venereol 93(4):475–476.  https://doi.org/10.2340/00015555-1502 PubMedCrossRefGoogle Scholar
  33. 33.
    Chua-Aguilera CJ, Möller B, Yawalkar N (2017) Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides. Clin Rev Allergy Immunol 53(3):371–393.  https://doi.org/10.1007/s12016-017-8632-5 PubMedCrossRefGoogle Scholar
  34. 34.
    Ali MM, Atwan AA, Gonzalez ML (2010) Cutaneous sarcoidosis: updates in the pathogenesis. J Eur Acad Dermatol Venereol JEADV 24(7):747–755.  https://doi.org/10.1111/j.1468-3083.2009.03517.x PubMedCrossRefGoogle Scholar
  35. 35.
    Ina Y, Takada K, Yamamoto M, Morishita M, Senda Y, Torii Y (1989) HLA and sarcoidosis in the Japanese. Chest 95(6):1257–1261.  https://doi.org/10.1378/chest.95.6.1257 PubMedCrossRefGoogle Scholar
  36. 36.
    Ishihara M, Ohno S (1997) Genetic influences on sarcoidosis. Eye Lond Engl 11(Pt 2):155–161.  https://doi.org/10.1038/eye.1997.44 Google Scholar
  37. 37.
    Barnard J, Rose C, Newman L, Canner M, Martyny J, McCammon C, Bresnitz E, Rossman M, Thompson B, Rybicki B, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Teirstein AS, Yeager H Jr, Johns CJ, Rabin DL, Cherniack R, ACCESS Research Group (2005) Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med 47(3):226–234.  https://doi.org/10.1097/01.jom.0000155711.88781.91 PubMedCrossRefGoogle Scholar
  38. 38.
    Oswald-Richter KA, Beachboard DC, Seeley EH, Abraham S, Shepherd BE, Jenkins CA, Culver DA, Caprioli RM, Drake WP (2012) Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol 32(5):1129–1140.  https://doi.org/10.1007/s10875-012-9700-5 PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Brownell I, Ramírez-Valle F, Sanchez M, Prystowsky S (2011) Evidence for mycobacteria in sarcoidosis. Am J Respir Cell Mol Biol 45(5):899–905.  https://doi.org/10.1165/rcmb.2010-0433TR PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Eishi Y (2013) Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. Biomed Res Int 2013:935289–935218.  https://doi.org/10.1155/2013/935289 PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Judson MA, Marchell RM, Mascelli M et al (2012) Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. J Am Acad Dermatol 66(6):901–910, 910.e1–2.  https://doi.org/10.1016/j.jaad.2011.06.017 PubMedCrossRefGoogle Scholar
  42. 42.
    Petroianni A, Halili I, Lagalla M, Mougkaraki E, Terzano C (2015) Sarcoidosis at onset of psoriasis: a common immunopathogenesis. Review and case report. Eur Rev Med Pharmacol Sci 19(10):1773–1778PubMedGoogle Scholar
  43. 43.
    Rosenbach M, English JC (2015) Reactive granulomatous dermatitis: a review of palisaded neutrophilic and granulomatous dermatitis, interstitial granulomatous dermatitis, interstitial granulomatous drug reaction, and a proposed reclassification. Dermatol Clin 33(3):373–387.  https://doi.org/10.1016/j.det.2015.03.005 PubMedCrossRefGoogle Scholar
  44. 44.
    Ehlers S, Schaible UE (2012) The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol 3:411.  https://doi.org/10.3389/fimmu.2012.00411 PubMedGoogle Scholar
  45. 45.
    Guirado E, Schlesinger LS, Kaplan G (2013) Macrophages in tuberculosis: friend or foe. Semin Immunopathol 35(5):563–583.  https://doi.org/10.1007/s00281-013-0388-2 PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Lugo-Villarino G, Vérollet C, Maridonneau-Parini I, Neyrolles O (2011) Macrophage polarization: convergence point targeted by mycobacterium tuberculosis and HIV. Front Immunol 2:43.  https://doi.org/10.3389/fimmu.2011.00043 PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Shaler CR, Horvath CN, Jeyanathan M, Xing Z (2013) Within the enemy’s camp: contribution of the granuloma to the dissemination, persistence and transmission of Mycobacterium tuberculosis. Front Immunol 4:30.  https://doi.org/10.3389/fimmu.2013.00030 PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Kalen JE, Shokeen D, Ramos-Caro F, Motaparthi K (2017) Palisaded neutrophilic granulomatous dermatitis: spectrum of histologic findings in a single patient. JAAD Case Rep 3(5):425–428.  https://doi.org/10.1016/j.jdcr.2017.06.010 PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Dahl MV (2007) Granuloma annulare: long-term follow-up. Arch Dermatol 143(7):946–947.  https://doi.org/10.1001/archderm.143.7.946 PubMedCrossRefGoogle Scholar
  50. 50.
    Li A, Hogan DJ, Sanusi ID, Smoller BR (2003) Granuloma annulare and malignant neoplasms. Am J Dermatopathol 25(2):113–116.  https://doi.org/10.1097/00000372-200304000-00004 PubMedCrossRefGoogle Scholar
  51. 51.
    Peyrí J, Moreno A, Marcoval J (2007) Necrobiosis lipoidica. Semin Cutan Med Surg 26(2):87–89.  https://doi.org/10.1016/j.sder.2007.02.004 PubMedCrossRefGoogle Scholar
  52. 52.
    Bakos RM, Cartell A, Bakos L (2012) Dermatoscopy of early-onset necrobiosis lipoidica. J Am Acad Dermatol 66(4):e143–e144.  https://doi.org/10.1016/j.jaad.2011.01.028 PubMedCrossRefGoogle Scholar
  53. 53.
    Lim C, Tschuchnigg M, Lim J (2006) Squamous cell carcinoma arising in an area of long-standing necrobiosis lipoidica. J Cutan Pathol 33(8):581–583.  https://doi.org/10.1111/j.1600-0560.2006.00487.x PubMedCrossRefGoogle Scholar
  54. 54.
    Mistry BD, Alavi A, Ali S, Mistry N (2017) A systematic review of the relationship between glycemic control and necrobiosis lipoidica diabeticorum in patients with diabetes mellitus. Int J Dermatol 56(12):1319–1327.  https://doi.org/10.1111/ijd.13610 PubMedCrossRefGoogle Scholar
  55. 55.
    Peckruhn M, Tittelbach J, Elsner P (2017) Update: treatment of necrobiosis lipoidica. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 15(2):151–157.  https://doi.org/10.1111/ddg.13186 Google Scholar
  56. 56.
    Durupt F, Dalle S, Debarbieux S, Balme B, Ronger S, Thomas L (2008) Successful treatment of necrobiosis lipoidica with antimalarial agents. Arch Dermatol 144(1):118–119.  https://doi.org/10.1001/archderm.144.1.118 PubMedCrossRefGoogle Scholar
  57. 57.
    Eberle FC, Ghoreschi K, Hertl M (2010) Fumaric acid esters in severe ulcerative necrobiosis lipoidica: a case report and evaluation of current therapies. Acta Derm Venereol 90(1):104–106.  https://doi.org/10.2340/00015555-0757 PubMedCrossRefGoogle Scholar
  58. 58.
    Gambichler T, Kreuter A, Freitag M, Pawlak FM, Brockmeyer NH, Altmeyer P (2003) Clearance of necrobiosis lipoidica with fumaric acid esters. Dermatol Basel Switz 207(4):422–424.  https://doi.org/10.1159/000074133 CrossRefGoogle Scholar
  59. 59.
    Sayah A, English JC (2005) Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 53(2):191–209; quiz 210-212.  https://doi.org/10.1016/j.jaad.2004.07.023 PubMedCrossRefGoogle Scholar
  60. 60.
    Sibbitt WL, Williams RC (1982) Cutaneous manifestations of rheumatoid arthritis. Int J Dermatol 21(10):563–572.  https://doi.org/10.1111/j.1365-4362.1982.tb02037.x PubMedCrossRefGoogle Scholar
  61. 61.
    Molina-Ruiz AM, Requena L (2015) Foreign body granulomas. Dermatol Clin 33(3):497–523.  https://doi.org/10.1016/j.det.2015.03.014 PubMedCrossRefGoogle Scholar
  62. 62.
    Alcântara CEP, Noronha MS, Cunha JF, Flores IL, Mesquita RA (2017) Granulomatous reaction to hyaluronic acid filler material in oral and perioral region: a case report and review of literature. J Cosmet Dermatol.  https://doi.org/10.1111/jocd.12374
  63. 63.
    Ledon JA, Savas JA, Yang S, Franca K, Camacho I, Nouri K (2013) Inflammatory nodules following soft tissue filler use: a review of causative agents, pathology and treatment options. Am J Clin Dermatol 14(5):401–411.  https://doi.org/10.1007/s40257-013-0043-7 PubMedCrossRefGoogle Scholar
  64. 64.
    Christianson JC, Engber W, Andes D (2003) Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts. Med Mycol 41(3):177–188.  https://doi.org/10.1080/1369378031000137224 PubMedCrossRefGoogle Scholar
  65. 65.
    van Zyl L, du Plessis J, Viljoen J (2015) Cutaneous tuberculosis overview and current treatment regimens. Tuberc Edinb Scotl 95(6):629–638.  https://doi.org/10.1016/j.tube.2014.12.006 CrossRefGoogle Scholar
  66. 66.
    Schmied E, Schmied C, Mainetti C (1990) Cutaneous manifestations of tuberculosis. Schweiz Rundsch Med Prax Rev Suisse Med Prax 79:1244–1249Google Scholar
  67. 67.
    Oryan A, Akbari M (2016) Worldwide risk factors in leishmaniasis. Asian Pac J Trop Med 9(10):925–932.  https://doi.org/10.1016/j.apjtm.2016.06.021 PubMedCrossRefGoogle Scholar
  68. 68.
    Oliveira-Ribeiro C, Pimentel MIF, De Oliveira RVC et al (2017) Clinical and laboratory profiles of patients with early spontaneous healing in cutaneous localized leishmaniasis: a historical cohort study. BMC Infect Dis 17(1):559.  https://doi.org/10.1186/s12879-017-2658-4 PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Uzun S, Durdu M, Culha G, Allahverdiyev AM, Memisoglu HR (2004) Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J Parasitol 90(4):853–859.  https://doi.org/10.1645/GE-185R PubMedCrossRefGoogle Scholar
  70. 70.
    Negi AK, Sharma NL, Mahajan VK et al (2007) Comparative efficacy of intralesional sodium stibogluconate (SSG) alone and its combination with intramuscular SSG to treat localized cutaneous leishmaniasis: results of a pilot study. Indian J Dermatol Venereol Leprol 73:280PubMedGoogle Scholar
  71. 71.
    Munir A, Janjua SA, Hussain I (2008) Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerol Croat ADC 16(2):60–64PubMedGoogle Scholar
  72. 72.
    Treatment of Skin Disease - 4th Edition. https://www.elsevier.com/books/treatment-of-skin-disease/lebwohl/978-0-7020-5235-4. Accessed 6 Dec 2017
  73. 73.
    Lamb RC, Dawn G (2014) Cutaneous non-tuberculous mycobacterial infections. Int J Dermatol 53(10):1197–1204.  https://doi.org/10.1111/ijd.12528 PubMedCrossRefGoogle Scholar
  74. 74.
    Gray SF, Smith RS, Reynolds NJ, Williams EW (1990) Fish tank granuloma. BMJ 300(6731):1069–1070.  https://doi.org/10.1136/bmj.300.6731.1069 PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Eberst E, Dereure O, Guillot B, Trento C, Terru D, van de Perre P, Godreuil S (2012) Epidemiological, clinical, and therapeutic pattern of Mycobacterium marinum infection: a retrospective series of 35 cases from southern France. J Am Acad Dermatol 66(1):e15–e16.  https://doi.org/10.1016/j.jaad.2011.01.024 PubMedCrossRefGoogle Scholar
  76. 76.
    Garzoni C, Adler S, Boller C, Furrer H, Villiger PM (2010) Possible role of anti-TNF monoclonal antibodies in the treatment of Mycobacterium marinum infection. Rheumatol Oxf Engl 49(10):1991–1993.  https://doi.org/10.1093/rheumatology/keq146 CrossRefGoogle Scholar
  77. 77.
    Aubry A, Chosidow O, Caumes E, Robert J, Cambau E (2002) Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 162(15):1746–1752.  https://doi.org/10.1001/archinte.162.15.1746 PubMedCrossRefGoogle Scholar
  78. 78.
    Uslan DZ, Kowalski TJ, Wengenack NL, Virk A, Wilson JW (2006) Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol 142(10):1287–1292.  https://doi.org/10.1001/archderm.142.10.1287 PubMedCrossRefGoogle Scholar
  79. 79.
    Drage LA, Ecker PM, Orenstein R, Phillips PK, Edson RS (2010) An outbreak of Mycobacterium chelonae infections in tattoos. J Am Acad Dermatol 62(3):501–506.  https://doi.org/10.1016/j.jaad.2009.03.034 PubMedCrossRefGoogle Scholar
  80. 80.
    Carbonne A, Brossier F, Arnaud I, Bougmiza I, Caumes E, Meningaud JP, Dubrou S, Jarlier V, Cambau E, Astagneau P (2009) Outbreak of nontuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. J Clin Microbiol 47(6):1961–1964.  https://doi.org/10.1128/JCM.00196-09 PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Gousseff M, Mechaï F, Lecuit M, Lortholary O (2008) Systemic granulomatosis of infectious origin. Rev Med Interne 29(1):15–27.  https://doi.org/10.1016/j.revmed.2007.09.037 PubMedCrossRefGoogle Scholar
  82. 82.
    Degitz K, Steidl M, Thomas P, Plewig G, Volkenandt M (1993) Aetiology of tuberculids. Lancet Lond Engl 341(8839):239–240.  https://doi.org/10.1016/0140-6736(93)90101-L CrossRefGoogle Scholar
  83. 83.
    Gupta V (2015) Papulonecrotic tuberculid with scrofuloderma: an uncommon association. J Clin Diagn Res JCDR 9:WD03–WD04.  https://doi.org/10.7860/JCDR/2015/10751.5524 PubMedGoogle Scholar
  84. 84.
    Greuter T, Navarini A, Vavricka SR (2017) Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol 53(3):413–427.  https://doi.org/10.1007/s12016-017-8617-4 PubMedCrossRefGoogle Scholar
  85. 85.
    Wanat KA, Rosenbach M (2014) A practical approach to cutaneous sarcoidosis. Am J Clin Dermatol 15(4):283–297.  https://doi.org/10.1007/s40257-014-0079-3 PubMedCrossRefGoogle Scholar
  86. 86.
    Giner T, Benoit S, Kneitz H, Goebeler M (2017) Sarcoidosis: dermatological view of a rare multisystem disease. Hautarzt Z Dermatol Venerol Verwandte Geb 68(7):526–535.  https://doi.org/10.1007/s00105-017-4005-5 CrossRefGoogle Scholar
  87. 87.
    Tchernev G (2006) Cutaneous sarcoidosis: the “great imitator”: etiopathogenesis, morphology, differential diagnosis, and clinical management. Am J Clin Dermatol 7(6):375–382.  https://doi.org/10.2165/00128071-200607060-00006 PubMedCrossRefGoogle Scholar
  88. 88.
    Tchernev G, Patterson JW, Nenoff P, Horn LC (2010) Sarcoidosis of the skin—a dermatological puzzle: important differential diagnostic aspects and guidelines for clinical and histopathological recognition. J Eur Acad Dermatol Venereol JEADV 24(2):125–137.  https://doi.org/10.1111/j.1468-3083.2009.03396.x PubMedCrossRefGoogle Scholar
  89. 89.
    Haimovic A, Sanchez M, Judson MA, Prystowsky S (2012) Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol 66(5):699.e1–699.18; quiz 717-718.  https://doi.org/10.1016/j.jaad.2011.11.965 CrossRefGoogle Scholar
  90. 90.
    Mañá J, Marcoval J (2012) Skin manifestations of sarcoidosis. Presse Medicale Paris Fr 1983 41(6):e355–e374.  https://doi.org/10.1016/j.lpm.2012.02.046 Google Scholar
  91. 91.
    Spiteri MA, Matthey F, Gordon T et al (1985) Lupus pernio: a clinico-radiological study of thirty-five cases. Br J Dermatol 112(3):315–322.  https://doi.org/10.1111/j.1365-2133.1985.tb04859.x PubMedCrossRefGoogle Scholar
  92. 92.
    Marcoval J, Mañá J, Rubio M (2011) Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol 36(7):739–744.  https://doi.org/10.1111/j.1365-2230.2011.04128.x PubMedCrossRefGoogle Scholar
  93. 93.
    Veien NK, Stahl D, Brodthagen H (1987) Cutaneous sarcoidosis in Caucasians. J Am Acad Dermatol 16(3):534–540.  https://doi.org/10.1016/S0190-9622(87)70070-X PubMedCrossRefGoogle Scholar
  94. 94.
    Heath CR, David J, Taylor SC (2012) Sarcoidosis: are there differences in your skin of color patients? J Am Acad Dermatol 66(1):121.e1–121.14.  https://doi.org/10.1016/j.jaad.2010.06.068 CrossRefGoogle Scholar
  95. 95.
    Rybicki BA, Iannuzzi MC (2007) Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med 28(1):22–35.  https://doi.org/10.1055/s-2007-970331 PubMedCrossRefGoogle Scholar
  96. 96.
    Rybicki BA, Major M, Popovich J, Maliank MJ, lannuzzi MC (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145(3):234–241.  https://doi.org/10.1093/oxfordjournals.aje.a009096 PubMedCrossRefGoogle Scholar
  97. 97.
    Young RJ, Gilson RT, Yanase D, Elston DM (2001) Cutaneous sarcoidosis. Int J Dermatol 40(4):249–253.  https://doi.org/10.1046/j.1365-4362.2001.01151.x PubMedCrossRefGoogle Scholar
  98. 98.
    Aubart FC, Ouayoun M, Brauner M, Attali P, Kambouchner M, Valeyre D, Nunes H (2006) Sinonasal involvement in sarcoidosis: a case-control study of 20 patients. Medicine (Baltimore) 85(6):365–371.  https://doi.org/10.1097/01.md.0000236955.79966.07 CrossRefGoogle Scholar
  99. 99.
    Baughman RP, Lower EE (2015) Treatment of sarcoidosis. Clin Rev Allergy Immunol 49(1):79–92.  https://doi.org/10.1007/s12016-015-8492-9 PubMedCrossRefGoogle Scholar
  100. 100.
    Baughman RP, Lower EE (2007) Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 25(3):334–340.  https://doi.org/10.1016/j.clindermatol.2007.03.011 PubMedCrossRefGoogle Scholar
  101. 101.
    Kouba DJ, Mimouni D, Rencic A, Nousari HC (2003) Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 148(1):147–148.  https://doi.org/10.1046/j.1365-2133.2003.05042.x PubMedCrossRefGoogle Scholar
  102. 102.
    Stagaki E, Mountford WK, Lackland DT, Judson MA (2009) The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 135(2):468–476.  https://doi.org/10.1378/chest.08-1347 PubMedCrossRefGoogle Scholar
  103. 103.
    Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L (2001) The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137(1):69–73PubMedCrossRefGoogle Scholar
  104. 104.
    Baughman RP, Judson MA, Lower EE et al (2016) Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG 32:289–295Google Scholar
  105. 105.
    Heidelberger V, Ingen-Housz-Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L, Caux F, Chapelon-Abric C, Debarbieux S, Delaporte E, Duval-Modeste AB, Fain O, Joly P, Marchand-Adam S, Monfort JB, Noël N, Passeron T, Ruivard M, Sarrot-Reynauld F, Verrot D, Bouvry D, Fardet L, Chosidow O, Sève P, Valeyre D (2017) Efficacy and tolerance of anti-tumor necrosis factor α agents in cutaneous sarcoidosis: a French study of 46 cases. JAMA Dermatol 153(7):681–685.  https://doi.org/10.1001/jamadermatol.2017.1162 PubMedCrossRefGoogle Scholar
  106. 106.
    Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE (2012) Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 148(2):262–264.  https://doi.org/10.1001/archdermatol.2011.301 PubMedCrossRefGoogle Scholar
  107. 107.
    Baughman RP, Lower EE (2004) Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. Am J Clin Dermatol 5(6):385–394.  https://doi.org/10.2165/00128071-200405060-00003 PubMedCrossRefGoogle Scholar
  108. 108.
    Nguyen YT, Dupuy A, Cordoliani F, Vignon-Pennamen MD, Lebbé C, Morel P, Rybojad M (2004) Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 50(2):235–241.  https://doi.org/10.1016/j.jaad.2003.07.006 PubMedCrossRefGoogle Scholar
  109. 109.
    Bohelay G, Bouaziz J-D, Nunes H, Rybojad M, Bagot M, Petit A, Laroche L (2014) Striking leflunomide efficacy against refractory cutaneous sarcoidosis. J Am Acad Dermatol 70(5):e111–e113.  https://doi.org/10.1016/j.jaad.2013.10.048 PubMedCrossRefGoogle Scholar
  110. 110.
    Israel HL, McComb BL (1991) Chlorambucil treatment of sarcoidosis. Sarcoidosis 8(1):35–41PubMedGoogle Scholar
  111. 111.
    Baughman RP, Lower EE (2004) Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG 21:43–48Google Scholar
  112. 112.
    Ackerman AB, Guo Y, Vitale PA, Vossaert K (1993) Clues to diagnosis in dermatopathology, vol 3. ASCP Press, Chicago, pp 309–312Google Scholar
  113. 113.
    Verneuil L, Dompmartin A, Comoz F, Pasquier CJ, Leroy D (2001) Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies. J Am Acad Dermatol 45(2):286–291.  https://doi.org/10.1067/mjd.2001.114577 PubMedCrossRefGoogle Scholar
  114. 114.
    Wang Y, Wu Y, Zheng Z, Bai Y, Cui Y (2017) Interstitial granulomatous dermatitis associated with primary biliary cirrhosis. J Dermatol.  https://doi.org/10.1111/1346-8138.13778
  115. 115.
    Schreckenberg C, Asch PH, Sibilia J, Walter S, Lipsker D, Heid E, Grosshans E (1998) Interstitial granulomatous dermatitis and paraneoplastic rheumatoid polyarthritis disclosing cancer of the lung. Ann Dermatol Venereol 125(9):585–588PubMedGoogle Scholar
  116. 116.
    Dodiuk-Gad RP, Shear NH (2015) Granulomatous drug eruptions. Dermatol Clin 33(3):525–539.  https://doi.org/10.1016/j.det.2015.03.015 PubMedCrossRefGoogle Scholar
  117. 117.
    Perrin C, Lacour JP, Castanet J, Michiels JF (2001) Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis. Am J Dermatopathol 23(4):295–298.  https://doi.org/10.1097/00000372-200108000-00003 PubMedCrossRefGoogle Scholar
  118. 118.
    Gerbing EK, Metze D, Luger TA, Ständer S (2003) Interstitial granulomatous dermatitis without arthritis: successful therapy with hydroxychloroquine. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 1:137–141Google Scholar
  119. 119.
    Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, Samuels A, Oghilikhan M, Gaspari A (2006) Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 142(2):198–202.  https://doi.org/10.1001/archderm.142.2.198 PubMedCrossRefGoogle Scholar
  120. 120.
    Schanz S, Schmalzing M, Guenova E, Metzler G, Ulmer A, Kötter I, Fierlbeck G (2012) Interstitial granulomatous dermatitis with arthritis responding to tocilizumab. Arch Dermatol 148(1):17–20.  https://doi.org/10.1001/archdermatol.2011.341 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Epatocentro TicinoLuganoSwitzerland
  2. 2.Department of DermatologyBellinzona Regional HospitalBellinzonaSwitzerland
  3. 3.Cité générationsOnexSwitzerland
  4. 4.Clinique de DermatologieHôpitaux Universitaires de GenèveGenèveSwitzerland

Personalised recommendations